Reading AYTU? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AYTU free→Reading AYTU? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AYTU free→QuarterlyIQ Insights · AYTU
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 13, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 third quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for May 13, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (available l…
Entry into a Definitive Material Agreement . As previously disclosed, Aytu BioPharma, Inc. (the “Company”) completed public equity offerings in June 2023 and June 2025 whereby the Company issued certain warrants and prefunded warrants (collectively, the “Warrants”) to certain institutional investors (the “Investors”). In connection with the preparation of its Quarterly Reports on Form 10-Q for the quarters ended September 30, 2025, and December 31, 2025, the Company with consultation with its…
Material Modification to Rights of Security Holders . See the disclosures in
Results of Operations and Financial Condition. See the disclosures in
Unregistered Sales of Equity Securities . See the disclosures in
Results of Operations and Financial Condition. On February 3, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 second quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for February 3, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (av…
Results of Operations and Financial Condition. On November 13, 2025, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 first quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for November 13, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (a…
Results of Operations and Financial Condition. On September 23, 2025, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2025 full year and fourth quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for September 23, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast…
Termination of Material Definitive Agreement. As previously disclosed in its United States Securities and Exchange Commission filings, Aytu BioPharma, Inc. (the “Company”) suspended its clinical development of AR101. In connection with this suspension, the Company has been engaged in negotiations with EnzCo, LLC (“EnzCo”) and Rumpus VEDS LLC, (“Rumpus VEDS”), Rumpus Therapeutics LLC, (“Rumpus Therapeutics”) and Rumpus Vascular LLC, (“Rumpus Vascular” and, together with Rumpus VEDS and Rumpus…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Entry into a Material Definitive Agreement. On June 20, 2025, Aytu BioPharma, Inc. (“Aytu” or the “Company”) entered into an Amendment No. 6 to Loan and Security Agreement (the “Eclipse Amendment”), by and among the Company, Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Aytu Therapeutics, LLC, PharmaFab Texas, LLC and Cherry Creek Therapeutics, Inc. (collectively, the “Borrowers”), Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC), as agent, and…
Entry into a Material Definitive Agreement. On June 5, 2025, Aytu BioPharma, Inc. (the “Company” or “Aytu”), entered into an Exclusive Commercialization Agreement (the “Agreement”) with Fabre-Kramer Holdings, Inc. (“Fabre-Kramer”), pursuant to which the Company acquired certain rights and obligations in connection with the commercialization of EXXUA™ (gepirone) extended release tablets, an FDA-approved pharmaceutical indicated for the treatment of Major Depressive Disorder (MDD) in adults, in…
Entry into a Material Definitive Agreement. On June 5, 2025, Aytu BioPharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as underwriter (the “Underwriter”), relating to the public offering of 1,366,668 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price per share of Common Stock of $1.50 (the “Offering Price”), and 8,233,332 prefunded warrants in lieu of Co…
Completion of Acquisition or Disposition of Assets. The information set forth under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As described under
Results of Operations and Financial Condition. On May 14, 2025, Aytu BioPharma, Inc. (the “Company” or “Aytu”) issued a press release announcing its fiscal 2025 third quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for May 14, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (a…
Results of Operations and Financial Condition. On February 12, 2025, Aytu BioPharma, Inc. (the “Company” or “Aytu”) issued a press release announcing its fiscal 2025 second quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for February 12, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and t…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.